Dermatology Consultation Service

咨询服务人员包括我本人，John DiGiovanna博士，以及2011年加入该科的护士执业医生Olanda Hathaway。如上所述，在皮肤病的评估和管理方面提供临床专业知识是对NIH社区的一项高度重视的服务，这一点在2007年获得了NIH主任奖的认可。除了咨询病人外，我还是其他分支机构发起的其他几个方案的副研究员，以及三个治疗方案的首席研究员(将另行讨论)。我目前作为副研究员参与的非皮肤科方案包括：GVHD的自然病史；恶性淋巴瘤/白血病的降低强度移植；免疫耗竭治疗和非亲属捐赠者的降低强度移植；DOCK8免疫缺陷的异基因移植；泊马度胺用于慢性GVHD；孟鲁司特治疗毛细支气管炎闭塞性肺病；埃洛替尼和贝伐单抗治疗肾细胞癌；自身炎症性疾病的自然病史；白塞病的Anakinra；IL-1拮抗剂缺乏的利洛那普。慢性移植物抗宿主病(GVHD)的合作工作是与NCI和非NCI研究GVHD自然病史的几个NCI和非NCI的主要多学科合作。根据我在这个小组的经验，我已经出版了几个关于皮肤GVHD的文本章节和临床手稿，并有幸在全国各地的不同组织(哈佛大学、塔夫茨大学、宾夕法尼亚大学、美国皮肤病学会、地区性皮肤病学会和世界皮肤病大会)演讲。通过繁忙的咨询服务，协作临床研究非常活跃。在几种周期性发热综合征患者中新发现的吡喃基因突变，以及对由此产生的自体炎症疾病有效的生物疗法的可获得性，将一组新的患者引入临床。我们现在正在系统地描述Papa综合征、白塞病和IL-1受体拮抗剂(DIRA)缺乏患者的皮肤表现并评估治疗反应。我目前是两个开放治疗方案的首席研究员：甲磺酸伊马替尼(08-C-0148)用于治疗硬化性慢性移植物抗宿主病(仅限数据分析)，Anakinra用于中性粒细胞脓疱性皮肤病(13-C-0071；招募)。

The Consult Service Staff consists of myself, Dr. John DiGiovanna, and a Nurse Practitioner, Olanda Hathaway, who joined the Branch in 2011. As mentioned above, providing clinical expertise in the assessment and management of the cutaneous disease is a highly valued service to the NIH community which was recognized by the NIH Director's Award in 2007. In addition to seeing patients in Consultation, I am an Associate Investigator on several other protocols initiated by other branches as well as a Principal Investigator on three therapeutic protocols (to be discussed separately). The current non-Dermatology Branch protocols in which I am an Associate Investigator include Natural History of GVHD; Reduced intensity transplants for malignant lymphomas/leukemias; Immune-depleting therapy and reduced intensity transplant using unrelated donors; Allogeneic transplant for DOCK8 Immunodeficiency; Pomalidomide for chronic GVHD; Phase II Montelukast for bronchiolitis obliterans; Erlotinib and bevacizumab for renal cell carcinoma; Natural history of auto-inflammatory diseases; Anakinra for Behcet's disease; Rilonacept for deficiency of the IL-1 antagonist. The chronic graft versus host disease (GVHD) collaborative effort is a major multidisciplinary collaboration with several NCI and non-NCI investigators studying the Natural history of GVHD. Based on my experience with this group, I have published several text chapters and clinical manuscripts on cutaneous GVHD and have been honored to lecture to various groups around the country (Harvard, Tufts, U. of Pennsylvania, the American Academy of Dermatology, regional dermatologic societies, and the World Congress of Dermatology.) Collaborative clinical research is extremely active via the busy consultation service. The newly discovered mutations in pyrin genes in patients with several periodic fever syndromes, and the availability of biologic therapies that have efficacy in the resulting autoinflammatory diseases have introduced a new group of patients to the clinic. We are now systematically characterizing cutaneous manifestations and assessing responses to treatment in patients with PAPA syndrome, Behcets and deficiency of IL-1 receptor antagonist (DIRA). I am currently Principal Investigator on two open therapeutic protocols: imatinib mesylate (08-C-0148) for the treatment of sclerotic chronic GVHD (data analysis only), and anakinra for neutrophilic pustular skin disease (13-C-0071; recruiting).